Because of their central role in the initiation and progression of CRC, blockade of the mTOR and PI3K signaling pathways has emerged as a compelling target for the development of novel CRC therapeutics [10], [56]–[59]. The gene discussed is PIK3CA; the disease is colorectal carcinoma.